Organ-Specific 3D Culture Platform

Despite demonstrating high efficacy in cell culture and animal models, over 95% of anticancer drugs do not reach patients because they fail clinical trials. Our platform is designed to evaluate drug candidates and drug combinations within the native microenvironment of human tissues.

Our technology is a patient-derived 3D culture platform that recreates the complex human organ microenvironment thereby preserving the critical interactions between a tumor and its surroundings. Our models replicate the extracellular matrix (ECM) of individual organs and disease-specific soluble microenvironment mimicking the biology of human disease, and as such, demonstrate high correlation with clinical response.

Applications

Drug candidate screening

Identification of new drug combinations

Rescue failed drug candidates

Evaluation of off-target toxicity

Target discovery

Biomarker discovery

Technology Advantages

Simulates complex human organ environment

Tumor microenvironment, which is composed of the cellular and extracellular elements that surround cancer cells, protects malignant cells from exogenous insults and renders tumor cells resistant to multiple therapeutic agents. Our platform incorporates both cellular and extracellular elements of tissue microenvironment in an organ- and disease-specific manner.

Extracellular components

extracellular matrix (ECM)
soluble factors (cytokines, etc.)

Cell-cell interactions

tumor-tumor interactions
tumor-stroma interactions

Preserves cellular composition

Our platform supports long-term survival and proliferation of malignant and non-malignant cellular components of tissues. This includes tumor cells, stroma, and immune components.

Exhibits high correlation with clinical response

Anticancer cancer compounds tested in our models exhibit high correlation with clinical response when comparing treatment outcomes in the clinic with cellular behavior in response to the therapeutic regimen. Our organ-specific technology is compatible with multiple drug classes, including small molecules, antibodies, antibody-drug conjugates (ADC), immunomodulatory agents, CAR-T cells, etc.

Fully customizable

Our platform is fully customizable to the tumor and tissue of interest. It is compatible with multiple cell types, drug classes, and downstream analysis methods.

Learn more